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INTRODUCTION 
Throughout the course of its existence, the Food and Drug Administration (FDA) has 
been a somewhat overlooked entity. That is, until the FDA proclaims that something on 
the American market available to consumers or doctors is unsafe or dangerous. The FDA 
is responsible for regulating almost all foods consumed by humans, domestic animals, 
and livestock. 1 In addition, the FDA regulates drugs, medical devices, biologics, 
cosmetics, and radiation-emitting devices. In 2015, the FDA issued an average of 12.5 
press releases each month.2 In contrast, the U.S. Department of Health and Human 
Services, which has similar goals of American consumer health and protection, issues 
an average of 7.5 press releases each month.3 
Press releases containing adverse publicity, e.g., that products or classes of products 
carry even the possibility of harm to the public, can be extremely harmful to the 
products' manufacturers occasionally compelling the manufacturers to voluntarily 
withdrawing the product.4 Traditionally, the FDA has enforced its statutory mandate 
by halting production or seizing tainted items before they reach the consumer market.5 
However, the FDA may be increasing its impact by relying more on press releases that 
warn the public that products might carry some harm, whether it is proven or unproven. 6 
And in today's world of breaking news stories getting through to the general public 
through social media platforms like Twitter (which limits each post to 140 characters or 
less), FDA press releases on the internet can create more misinformation and panic for 
consumers and manufactures alike with every re-tweet.7 
In addition, the FDA may use negative press releases as a threat, to effectively pressure 
manufacturers to comply with regulations or voluntarily recall products. Manufacturers 
may decide to incur the costs of voluntary compliance, instead of seeing their brands 
harmed. In 1959, the FDA broadly announced that cranberries harvested in Washington 
State and Oregon might be hazardous, because they had been treated with pesticides 
that caused cancer in laboratory rats. 8 While the FDA warning may have had some 
1 21 U.S.C. §§ 332, 334, 375 (2014) (outlining the FDA's role); but see§§ and 457(c) 
l""""'"""''"the U.S. Food and Inspection Service (FSIS) to regulate the U.S. commercial 
of meat, poultry, and egg ""''"U<"'ec' 1 
2 Press Announcements, FDA, 
PressAnnouncements/2015/defaulthtm. 




that the FDA has made inaccurate statements that have 
7 Michael Barthel et al., The 
CENTER 16, 2015), 
twitter-and-face book/ (explaining that social media users across demographics increasingly use 
social media as their main source of news, --,·--·-··, news events as the events are 
""f·'f.'"rn"'" which can lead to misinformation). 
8 Lisa M. Willis, Third-Year Paper, No cnmo•en·zes 
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positive effect, it failed to mention that only 1 percent of the cranberries grown in that 
region were contaminated.9 As a result, many perfectly good cranberries went unsold 
and producers were unduly harmed. 10 This example demonstrates the significant impact 
of one public statement from the FDA. 11 
In the hyper-connected modem age, an FDA press release can impact manufacturers 
and consumers in a matter of minutes. In recent years, the FDA, recognizing that press 
releases are influential and cost-effective, has used them more and more often to regulate 
products, particularly medical devices. 12 Overall, the numbers of FDA injunctions and 
seizures have increased proportionally with the amount of recall events within the press 
releases. However, these numbers are steadily increasing each year. 13 Unfortunately, 
thus far, the FDA's press releases have not been wholly accurate. 14 Quite often, the 
press releases contain alleged violations, which the internet can inflate, misreport, and 
spread incredibly fast. The FDA has failed to use their power of publicity in a way that 
best guides consumers and manufacturers alike. In order to better this unfortunate use 
of power, the FDA must recognize that when adverse publicity is made available to the 
public, the effects of such publicity go beyond the product or good at issue. Once that is 
recognized, the solution is another obstacle the agency must face in the modem internet 
age of irrevocable statements. Through an in-depth look at the handling of one medical 
device, the issues of the FD A's use of publicity will be assessed, possible solutions to 
the overall problem observed. Such solutions will then be addressed, hypothetically, to 
the problem at issue in order to demonstrate how the FDA could potentially reign in its 
abuse of publicity in such a fashion that would benefit all parties. 
I. THE PROBLEM 
Publicity has many benefits because it can quickly alert consumers ofhazardous products. 
However, adverse publicity can cause undue harm on the manufacturers, that may 
outweigh the benefit to consumers. Adverse publicity may be viewed as the deprivation 
of a private person or firm's right to engage in commerce and free enterprise, without 
the due process of law normally associated with government action. 15 In other words, 
if the government makes a negative statement about a private actor or its product, the 
private actor has no recourse, even if the statement is false. 16 The private actor can only 
9 Id. at 6. 
10 Id. 
ll 21US.C.§375 (2014). 
12 FDA Statistics Fiscal Year 2012, FDA (2013), 
downloads/I CEClJEnfrircementActions/U CM346964. 
13 Id 
14 See that the FDA 
of all fruits grown in Chile, after that grapes grmvn in Chile had been vrn,rnn,,u 
and grapes in the US. market). 
and the FDA, An 
16 Id 
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hope the government uses common sense and does not abuse its discretion. 17 Moreover, 
judicial review and potential monetary compensation for market losses cannot undo the 
widespread effects of erroneous adverse publicity because, with sovereign immunity, 
such judicial review is unavailable to those injured. 18 A negative FDA press release 
can have lasting harm to a particular product's marketing or to a manufacturer's overall 
reputation, even if the press release is later proved to be true only in part. 19 For example, 
in the mid-1990s, the U.S. Embassy in Chile received two anonymous tips that grapes 
grown in Chile and shipped to the United States had been contaminated with cyanide.20 
The FDA then found puncture marks in two Chilean grapes, quickly concluded the 
anonymous tips must be true, and banned all Chilean fruits from entering the United 
States.21 The FDA took this broad action even though it found no signs of contamination 
whatsoever in a second batch of Chilean grapes.22 Unsurprisingly, Chilean fruit suffered 
economically in the American marketplace as a result of the scare generated from the 
FDA's press release regarding possible contamination.23 
FDA press releases that mislead American consumers and the general marketplace 
have dramatic and widespread effects. Unfortunately, broad, initial negative statements 
about products attract more attention than subsequent corrections or retractions. In one 
study, 160 newspapers reported negative information about a product - but only half 
of those newspapers published a retraction.24 Even when a statement is not an outright 
press release from the FDA, statements from sources viewed by the general public 
as associated with the FDA can still have negative consequences for those whom are 
concerned with the subject material. 25 Even though the FDA does not intentionally create 
this misunderstanding, it still causes great harm to the manufacturers and producers at 
issue.26 For example, in summer 2014, FDA branch chief Monica Metz claimed, in the 
form of a constituent update posted on FDA's website, that the agency planned to ban 
the traditional technique of aging artisan cheeses on wooden shelves, citing the risk of 
bacteria growth.27 It was not an official press release but still scared many American 
cheesemakers and cheese lovers. 
17 Id. 
18 FederalTort Claims Act (FTCA), 28 US.C. § 2680 (2014) \b'~"''"" omviv'"" 1m1nUintyto the 
government "any claim based upon an act or omission of an of the Government, 
vAvivio•rns due care, in the execution of a statute or based upon the exercise or 
f":"1mmou11,,•c--...m the part of a federal agency or an of the Government, whether or not the 
discretion involved be abused."). 
19 Willis supra note 8, at 5 that a press release can lead to 
and decreased stock market value). 
2° Fisher Bros. Sales, Inc. US., 46 F.3d 279, 282 
21 Id. at 287. 
22 Id. 
Cir. 1995). 
24 Inron~arwnDisclosure, § 25.01 (2015). 
suits, brand 
:hP.PSPmnkinP-. FDA (June 11, 2014) 
26 Id. 
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Considering the FDA's influence, it must exercise greater caution before issuing 
negative information about consumer products. If the FDA reasonably believes, but 
has not confirmed, that a product will threaten American consumers' lives, it may 
need to disseminate a warning immediately. In a situation like this, an immediate and 
effective press release can be a great exception to the need for caution and careful steps. 
Unfortunately, the FDA has not created any procedure for this kind of exceptional 
situation, which would probably require consultation with outside experts and an 
immediate recall of the product.28 The FDA would benefit from such a procedure: 
for example, it would have been extremely helpful in early 2014, when the FDA first 
encountered a crisis centering on power morcellators. 29 This crisis has continued 
for months and has even prompted the U.S. House of Representatives to call for an 
investigation of the FDA's regulation of medical devices.30 
Another growing concern is that the FDA fails to perform the investigations and audits 
that may help regulated entities to comply voluntarily and avoid adverse publicity.31 
In 2011, the FDA failed to perform its own audits of facilities associated with food 
preparation in one-third of U.S. states; instead, it relied on state entities' inspections of 
those facilities. 32 The FDA has also reduced its staff and conducted fewer food product 
safety tests, even as manufacturers have initiated a greater number of food recalls, over 
the past fifteen years.33 Instead, the FDA has used broadly worded and inexpensive 
press releases to compel manufacturers to voluntarily recall their products.34 If the FDA 
continues to use press releases to enforce its regulations, it must try to decrease the 
chance of undue alarm and misinformation, and not harm companies that are in full 
compliance with the FDCA. 
28 Power Morcellator Activist Protests FDA Failure to Ban Uterine Morcellation, BERNSTEIN 
LIEBHARD LLP (Nov. 11, 2014), http://WV1-w.pmewswire.com/news-releases/power-morcellator-
activist-protests-f da-failure-to-ban-uterine-morcellation-bernstein-liebhard-llp-reports-2813 23621. 
html Dr. Amy Reed, doctor and cancer 
recall of the power morcellator, a medical device 
used in minimally invasive <11rapr·1,,< and furiously upset with the lack of action and several months 
of time the FDA spent recall of the medical device that possibly causes 
uterine cancer). 
29 Id. 
30 Jennifer Levitz, House Passes Bill to Improve 
J. (July 12, 2015) available at htt0n·//umJwmo1 
monitoring-of-medical-devices-1436736213. 
31 Vulnerabilities in FDA s Inspections, HHS OFFICE OF INSPECTOR 
GENERAL (2011 ), hhs.gov/oei/reports/oei-02-09-00430.pdf. 
32 Id. 
33 David Morgan, Despite Food Scares, FDA Cuts Inspections, CBS (Feb. 26, 2007), nrnr1r"1'"·w 
cbsnews.com/news/ despite-food-scares-fda-cuts-inspections/. 
34 FDA Enforcement Statistics Summary Fiscal Year 2013, supra note 12. 
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II. UNDERSTANDING THE OBSTACLE 
A manufacturer unduly harmed by an inaccurate or overblown press release has little 
recourse, largely because the FDA has broad discretion to act against potentially harmful 
products.35 Furthermore, the Federal Tort Claims Act (FTCA) generally protects federal 
government entities from liability.36 As a result, the FDA can only be found liable 
for breaching its duty of care.37 However, since Congress has declared that the FDA 
alone has the expertise to ensure that foods, drugs, and medical devices are safe for 
public use, courts are unlikely to second-guess the FDA's decisions.38 This discretion 
is reflected in the Administrative Procedures Act ("APA"), which directs courts to defer 
to most decisions by the FDA and other administrative agencies.39 Consequently, it 
is quite unlikely that a court will find that the FDA erred when the agency issued a 
precautionary press release.40 Upon creating the FDA, Congress primarily intended to 
do away with Sinclairian producers and manufacturers.41 Congress simply assumed that 
the FDA would exercise good reasoning while seeking to improve health and safety in 
the American marketplace. 
When adverse publicity results in a company's demise, it is difficult to build each 
necessary part of the case against the FDA. First, a plaintiff must exhaust all available 
agency remedies and fulfill other difficult requirements to overcome the FTCA's general 
grant of sovereign immunity. 42 Even then, the plaintiff must demonstrate that the FD A's 
negative press release caused its economic harm.43 It will be difficult to establish that 
the FDA's statements about a company's alleged violations of the FDCA proximately 
caused consumers to abandon the company's products. It is possible that consumers 
simply preferred competing products and the market worked as it should. Even if the 
plaintiff can prove causation, the plaintiff must then prove its harms. These hurdles may 
dissuade some plaintiffs for even seeking judicial redress. 
35 28 U.S.C. § 2680 (2012) (granting discretion to the FDA and limiting judicial review of the 
FDA's actions). 
36 Id. 
37 Mark Niles, but The Federal Tort Claims Act and the Scope 
Immunity, 54 ADMIN. L. REv. 1275 (2002). 
38 21 U.S.C. § (2012). 
39 Administrative Procedure Act, 5 U.S.C. § 706 (2012) (providing that judicial review is only 
warranted when administrative agencies act contrary to, or in excess of, statutory or constitutional 
authority). 
40 See Lars Noah, Governance the Backdoor: Administrative at the FDA, 93 
NEB. L. REV. 89, l 28 (2014) (suggesting that adverse publicity is a form ofa procedural short cut 
that the FDA uses to avoid jmlicial proceedings). 
41 See UPTON SINCLAIR, THE JuNGLE (See Sharp Press 2003) (1906) (exposing hazardous 
conditions and health code violations of workplaces within the meat-packing industry). 
42 See 5 U.S.C. § 704 (outlining administrative exhaustion requirement). 
43 Mizokami v. United States, 414 F.2d 1375, 1376-77, 1381 (Ct. Cl. 1969) (obtaining a private 
bill from Congress to waive FDA's sovereign immunity and determining that "sufficient connection 
had been proven between the [FDA] 's actions and the alleged losses"). In Mizokami, a private law 
allowed plaintiff vegetable growers who claimed that their spinach crops were contaminated with 
pc>ul01uc> to file suit FDA. Id. at 1376-77. Along with waiving FDA's immunity, the bill also 
for the actions and left it to the comt to decide damages for 
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A negative press release has lasting effects on manufacturers and consumers. Adverse 
publicity lingers even after the information is found to be untrue.44 Unfortunately, the 
FDA rarely issues corrections and retractions; when the FDA does, it receives much less 
attention, and it might create even more confusion about whether the products are safe.4s 
Specifically, the FDA only revisits a negative statement after determining that everything 
possible to improve or completely remove the product from the market has been done, 
and after several FDA offices coordinate in writing with one another.46 Therefore, it is 
difficult for manufacturers to recover from adverse publicity. 
A. Internet Pains and Not Enough Gains 
The FDA's failings in issuing press releases, which potentially cause undue recalls 
and consumer misinformation, are compounded by the nature of the World Wide Web. 
Most unfortunately, the "Internet serves as a content multiplier, and when capital 
markets seize information without verifying the details, the velocity and severity of the 
fallout can be even greater."47 The FDA and other government agencies particularly 
struggle to communicate accurately over social media sites like Twitter, which call 
for a brief statement and a link to a formal press release. The FDA's recent social 
media campaign through the FDA Adverse Event Reporting System (FAERS) is a 
perfect example.48 This proposed system would search the Internet for adverse events 
involving regulated products, which have not yet been reported to the FDA.49 The 
FDA's guidance document on the proposed system focuses on how food and drug 
manufacturers should be properly labeling and marketing their products on social 
media outlets.so It even discusses how to address Twitter's 140-character limit.SI The 
system would empower consumers to report perceived violations of the FDCA directly 
44 See Nathan Cortez, Adverse Publicity in the Internet Era, 2011 
BYU L. REv. 1371, 1403 (2011) (suggesting that the FDA often acts on "limited information and 
scientific uncertainty"). 
45 See 21 C.FR § 7.55(a) (2015) (outlining the steps for terminating an FDA recall). 
46 Id. A recall will be terminated when the Food and Drug Administration determines that all 
reasonable efforts have been made to remove or correct the product in accordance with the recall 
strategy, and when it is reasonable to assume that the product subject to the recall has been removed 
and proper disposition or correction has been made commensurate with the degree of hazard of the 
recalled product Written notification that a recall is terminated will be issued the appropriate 
Food and Drug Administration district office to the recalling firm 
47 Cortez, supra note 44 at 1401. 
48 Event Surveillance, FDA, http://V1;ww.fda.gov/ 
ScienceResearch/SpecialTopics/RegulatoryScience/ucm455305.htm 
49 Id 
on Social lvfedia and Internet 
Communications About Medical Products: Designed with Patients in Mind, FDA VOICE BLOG (June 
17, 2014 ), http:/iblogs.fda.gov/fdavoice/index.php/2014/06/fda-issues-draft-guidances-for-industry-
on-social-media-and-internet-communications-about-medical-products-designed-with-patients-in-
mind/. 
51 Internet/Social Media Platforms with Character Space 
limitations- Presenting Risk and Prescription Drugs and 
Medical Devices (Draft FDA (2014), http://www.fda.gov/downloads/Drugs/ 
GuidanceComplianceRegnlatoryinformation/Guidances1UCM401087.pdf 
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to the FDA.52 However, many commentators, including physicians, were quite dubious 
that the FDA would be able to process and analyze these reports.53 It could simply be 
seen as the FDA trying to keep up with the times. 
In general, consumer panic about a particular product could prevent the manufacturer 
from telling its side of the story and might lead to the collapse of that manufacturer or 
the entire industry. As long as the internet remains an unfiltered and unregulated world 
ofbloggers and news watchdogs, the FDA must attempt to issue accurate statements and 
discourage the public from overreacting and furthering unfounded allegations.54 
The FD A's use of the internet has only intensified its ability to create adverse publicity. 
There is a grave possibility that FDA statements will spread too quickly and become 
distorted before manufacturers can properly respond.55 Furthermore, the FDA is not 
required to give advanced notice to manufacturers before issuing press releases.56 
Manufacturers may be caught entirely off-guard and may struggle to respond accurately 
and effectively to the public and to government regulators. 
The FD A's broad communication can reach consumers in numerous ways. In print alone, 
agency publications like the FDA Consumer reach a circulation of more than 25,000 
paid subscribers.57 Furthermore, an individual may sign up for multiple FDA mailing 
lists, which can add up to 4 emails a day. This high number of original communications 
from the FDA can then become twisted and misconstrued on the internet as they are 
removed and become indirect communications, in ways that even the most sensationalist 
newspapers of the FDA's early days could not imagine because of the multiple levels 
between the actual source and what the audiences consumes.58 So when an initial 
press release is inaccurate or incomplete, it is even more likely that the press release's 
dissemination on the internet will create panic. 
While the FDA cannot control everything that is said on the Internet or in the press, the 
FDA should maintain better control, self-restraint, and due diligence in making sure 
that its press releases are as factually sound and clear as possible.59 Such control could 
include consulting with experts outside of the agency when necessary and investigating 
matters further before releasing negative press releases, especially when there are no 
members of the FDA specialized and duly prepared to assess a particular product. 
52 See Abrams, supra note 50 that the focus of the social media is for 
the consumer). 
53 Lena J. Weiner, FDA s Social 1\!edia Gambit 'A Long Shot,' Says Patient Advocate, HEALTH 
LEADERS MEDIA (August 13, 2014 6:45 AM) 
See Cortez, supra note 44, at 1395 \ rn~;cu:ssn1g 
social media). 
56 Johnson, supra note 15, at 10. 
57 Id. at 13. 
58 Cortez, supra note 44, at 1371. 
59 Id. at 1376. 
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B. What the FDA World Needs Now 
Consumers, manufacturers, and retailers alike deserve a better process through 
which they can learn about truly dangerous or unsafe products. The FDA should only 
communicate reliable, factual, and timely information about investigations of products 
and manufacturers, including whether those investigations are pending or completed. 
In addition, the FDA must consider the public's likely reaction before making any 
announcement, to minimize the possibility of harm and maximize the potential of 
protecting consumers. In other words, the FDA should inform consumers about 
dangerous products, but should not push consumers to become hostile towards any 
brand or industry. By striking this balance, the FDA can ensure consumer safety without 
creating undue consumer panic. 
III. THE PROBLEM AS FOUND IN TODAY'S HEADLINES 
A. The Tragedy 
The FDA demonstrated its ability to create chaos and confusion in its recent treatment of 
the laparoscopic power morcellator (LPM). An LPM is used to perform hysterectomies 
(surgical removal of the uterus) and myomectomy (surgical removal ofuterine fibroids). 60 
FDA regulation of the LPM began, like its regulation of many products, with tragedy. 
Specifically, the FDA took notice of Dr. Amy Reed's campaign to demonstrate how 
a common procedure used to remove otherwise benign uterine fibroids from women 
could actually lead to cancer.61 Fibroids are common, benign uterine growths that can 
be easily removed and most of the time are recommended to be removed, as the growths 
could later become cancerous.62 However, the LPM was found, in certain cases, to leave 
behind portions of the fibroid within the woman's uterus and become malignant some 
months, or sometimes sooner, after the procedure.63 After this occurred to Dr. Reed, she 
resolved to publicize the procedure's risks. 
The LPM's use in myomectomies has been and continues to be praised by some.64 In 
April 2014, the FDA estimated that this surgery is performed at least 50,000 times in 
the United States each year.65 It is minimally invasive, requires very little recovery time, 
and generally succeeds at removing uterine fibroids from a place where they would 
be too small to develop samples to test for cancer prior to the fibroids removal.66 The 
LPM's spinning blade slices fibroid tissue into smaller pieces and removes those pieces 
61 JENNIFER LEVlTZ & JoN KAMP, DEADLY MEDICINE: A COMMON SLJRGERY FOR WOMEN AND THE CANCER 
IT LEAVES BEHIND 34, 53, 67 St J. ed. 2014). 
62 Id. at 9-12. 
63 FDA, 2014 Press Release, supra note 60. 
64 LEVITZ & KAMP, note 61, at 49-50, 56. 
65 Id at23. 
66 at 9-10, 12-13. 
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through small incisions.67 This procedure may be performed with a bag to catch spare 
pieces of the fibroids that can spread into the uterus.68 Unless the gynecologist uses a 
bag with the LPM, some of the fibroid fragments may spread and be left behind in the 
uterus after surgery. 69 However, gynecologists routinely used the LPM device without 
a bag in removing uterine fibroids. 70 
Dr. Reed, an anesthesiologist and mother of six, is attempting to use her own experience 
to push the FDA to regulate the LPM. She had the basic surgery to remove uterine 
fibroid tumors using the LPM, but eight days later, she learned it had worsened her 
prognosis by spreading cancer from the remaining uterine fibroids. 71 The shredding 
of the fibroid inadvertently spread the undetected cancer because the fragments were 
uncontained. 72 Throughout fall 2014, while Dr. Reed's cancer had progressed to stage 
four, her husband focused on writing letters to the FDA, questioning its failure to act 
about the potentially deadly medical device.73 While many agree with Dr. Reed's calls 
for action, others argue that the device is safe and that the FDA created a mountain out 
ofa few exaggerated facts. 74 
At the time of this writing, Dr. Reed had a recurrence of her cancer, a tumor in her 
spine, but that has not stopped her avid fight for justice.75 She is now involved in an 
FBI investigation about whether the device's manufacturer, Johnson & Johnson, knew 
about the risks as early as 2006.76 Dr. Reed argues that she and other patients should 
have been better protected and this story involves "a violation of federal law that has led 
to the loss oflife."77 
67 Jon Kamp, More Health Insurers Take Action to Curb Morcellator Use, WALL ST. l (Apr. 
2, 2015), available at http:/ /wwwwsj.com/articles/more-health-insurers-take-action-to-limit-
morcellator-use-1428009386. 
68 Id 
69 LEVITZ & KAMP, supra note 61, at 24. 
70 Id. at 24-25. 
71 Id. at 13-15. 
72 Doctor with Cancer Raises Alarm about lvledical Device, CBS NEWS (June 4, 2015), 
cbsnews.com/news/ doctor-with-cancer-morcellator-medical-device/. 
73 BERNSTEIN Lrnm!ARJJ LLP, supra note 28. 
74 Jennifer Levitz & Jon Kamp, Resist FDA Tool, WALL ST. J 
(Sept 21, 2014 ), available at http:/ /,;vww wsj .com/articles/ gynecologists-push-back-on-fdas-caution-
a bout-cancer-when-using-morcellation-in-hysterectomies-1411358341 (reporting that obstetrics and 
gYJ1ecolo1g1sts alike were over the use LPMS in even after the FDA d1sc01lfaJ~ed 
their use); see also Jon Kamp, J&J's lvforcellator Sales Leaves Others, 
WALL ST. J (Sept 23, 2014 ), http://blogs.wsj.com/corporate-intelligence/2014/09/23/jjs-exit-from-
morcellator-sales-leaves-opportunities-for-others/. 
75 CBS NEws, supra note 72. 
76 Id 
77 Id; see also BERNSTEIN LIEBHARD LLP, supra note 28. 
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B. The First Press Release 
In April 2014, the FDA issued its first press release regarding the LPM. 7s However, the 
press release simply asked doctors to reconsider the possibilities of harm posed by use 
of the LPM: a less than useful recommendation. With separate statements of caution, 
warning, and urging of doubt regarding the procedure's benefits and risks, the FDA's 
press release revealed that the benefits of the device may be limited due to the potential 
development after surgery, of uterine sarcoma, that had not been found or realized prior 
to surgery.79 The release itself was extremely limited and offered little research data or 
clarity about the device's use in the future.so However, the press release did claim that 
the LPM causes cancer in 1 in 350 women and further stated: 
There is a risk that the procedure will spread the cancerous tissue within the 
abdomen and pelvis, significantly worsening the patient's likelihood of long-
term survival. For this reason, and because there is no reliable method for 
predicting whether a woman with fibroids may have a uterine sarcoma, the FDA 
discourages the use of laparoscopic power morcellation during hysterectomy 
or myomectomy for uterine fibroids.s 1 
The FDA admitted that this reasoning was based on only a survey of the small amount 
of information on the dangers of the medical device available at the time. s2 While the 
concern for the medical device had been slowly growing since approximately 2006, 
available information and studies about the device had unfortunately not increased. In 
the April 2014 press release, the FDA also promised that an advisory committee would 
review the device's risks in more detail that July. s3 Unfortunately, that committee only 
conducted a general review of nine studies (one of which was only in abstract form).s4 
For the next five months, the FDA did not take any further actions regarding this 
potentially cancer-inducing surgical device. During the FDA's period of silence, 
individual and institutional providers offered their opinions about whether the device 
should remain on the market. ss Many also criticized the FDA for discouraging use of 
the device but not actually recalling the device or offering any conclusive answers. s6 
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C. The Reaction 
Following the FDA advisory committee's July 2014 meeting on the LPM numerous 
U.S. doctors and hospitals, citing years of mistrust of the LPM, asked the FDA to 
announce a complete recall. 87 The leading LPM manufacturer, Johnson & Johnson, 
announced that it would keep its version from the market until the FDA made a 
conclusion about the LPM's safety.88 BlueCross/BlueShield, Highmark, and other 
health insurance providers quickly followed suit by discontinuing reimbursement for 
procedures that used the LPM. 89 
However, this was not a one-sided debate. Other patients, doctors, hospitals, and 
manufacturers argued that the FDA was making a mountain out of a perfectly fine and 
functional molehill. 90 Many wondered whether the FDA had overstepped its boundaries 
by declaring that 1 in 350 women treated with the LPM would develop cancer, without 
offering conclusive support for that statement.91 Some doctors proposed that the FDA's 
risk analysis was incorrect and that the actual risk of undetected sarcoma developing 
after the surgery was more likely to be 1 in 300.92 Some commentators suggested that 
the FDA should have considered patients' ages, history of other cancers, and other traits 
that might have affect the benefits and risks of using the LPM to remove fibroids. 93 
While manufacturers and healthcare providers had varying opinions about the LPM, it 
became clear that those opinions could have helped FDA earlier in the process. 
D. The Second Press Release 
On November 24, 2014, the FDA issued a second press release that further discouraged 
use of the LPM to remove uterine fibroids. 94 The FDA then suggested that "immediately 
in effect," LPM packaging should include two additional safety wamings.95 First, the 
packaging should display a "black box waming"96 disclosing that the operation could 
increase the risk of spreading cancer throughout the body and worsen the patient's 
likelihood oflong-term survival.97 Second, the packaging must list contraindications for 
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use of the LPM.98 Overall, the second FDA press release encouraged doctors to have 
more discussion of the LPM's risks and benefits with their patients.99 The FDA further 
promised that it would continue monitoring adverse event reports and information as it 
became available on the medical device to protect public health. 100 However, the FDA's 
assurance could be viewed as insufficient given the delayed warning. 
E. The Silver Lining 
Before the FDA's advisory committee convened and issued its conclusions in its second 
press release, other stakeholders - manufacturers, doctors, hospitals, and insurers-
conducted their own fruitful discussion. However, one group above all clearly benefited 
from the FDA's final conclusion: women considering procedures using the LPM. 
Following the FDA's second press release, those women and their providers better knew 
what to consider before choosing to use the LPM. The FDA was most useful when 
it organized and disclosed all of the stakeholders' competing arguments and helped 
patients to make their own informed decisions. 
The FDA's actions prompted each patient and her doctor to engage in a more sustained 
dialogue about whether to use the LPM. The FDA has also prompted doctors to ask 
patients to sign informed consent forms before undergoing procedures, to share videos 
of the LPM's use with other doctors, and to keep asking whether the LPM surgery is the 
best option for each patient. 101 So while the FDA took almost five months to issue its 
much-needed second press release, the FDA did help to initiate conversations between 
patients and doctors. Admittedly, during the delay, patients and other stakeholders may 
have begun to rely on the FDA's inaction and may have concluded on their own that the 
FDA would not issue a recall of LPMs. However, either way, the process was beneficial 
because patients began reviewing their options and making more educated decisions. 
Despite this eventual success, the FDA has been criticized for its handling of the 
LPM device. For example, a majority of doctors surveyed by the Wall Street Journal 
agreed that the FDA should update its methods of regulating medical devices such as 
the LPM. 102 Other government agencies are reviewing the FDA's actions and trying 
to ensure that this does not happen again. The FBI is currently considering the FDA's 
ability to effectively regulate medical devices, specifically since it initially approved 
the LPM, which clearly carries some risks. 103 The FBI is conducting a second, separate 
investigation centering on the LPM itself. 104 While the FBI acknowledges that the FDA 
made the right moves toward resolving the issue with the medical device by requiring 
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new warning labels on the product, the FBI is still seeking to find what information 
should have come to light before even the first FDA press release back in July 2014. 105 
Finally, members of the U.S. House of Representatives, in response to the LPM crisis, 
have proposed an amendment to the "21st Century Cures" Act that would require more 
Congressional oversight on the FDA's methodologies in determining whether a device 
is "generally recognized as safe" for use in the marketplace. 106 
IV. RECOMMENDED SOLUTIONS 
With some reforms, the FDA can better inform American consumers about medical 
devices and other consumer products. The FDA should ensure that the information 
in each press release is thorough and well-supported by sufficient facts. 107 The FDA 
should offer a notice and comment period to experts and stakeholders or should resolve 
all material questions before issuing a press release, whenever it is possible to do so. 108 
The FDA should also consider the public's knowledge of a product and the potential 
for confusion, before rushing to issue a press release. 109 The FDA must also become 
more effective at retracting and correcting negative statements, to effectively inform 
the public and minimize undue harm to manufacturers. 110 In addition to FDA reforms, 
private actors harmed by adverse publicity should be able to seek compensation when 
they are harmed by inappropriate FDA action. 111 
The LPM crisis demonstrates that the FDA should also find some way to address 
emergency situations involving products that are already on the market. The FDA should 
establish a taskforce that will respond to tips received through the new FAERS system. 112 
Finally, the FDA must amend and retract flawed statements more effectively. 113 This 
solution to the abuse and misuse of the FD A's power of publicity could come in the form 
of an adjustment to the Administrative Procedure Act (APA) or the FDCA itself, through 
the possible creation of an amendment to the FDCA. No matter where this amendment 
occurs, it should include a higher standard of proof and research behind each press 
release, notice to companies and industries prior to release, proper termination of recalls 
and the mandate of corrective press releases, increased overall self-restraint by the FDA, 
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and the creation of a task force that can quickly respond when there is a legitimate threat 
of seriously harmful products. 114 
A. Better Research 
If the FDA is required to be more thorough and careful when drafting a press release, 
it will be less likely to cause harm. 115 Instead, the resulting press release will be more 
reliable and beneficial to the public. 116 Also, by always making sure that there is some 
level of outside, specialized expert opinion involved in a press release regarding 
the specific product and its functions, adverse publicity will be less likely to have 
misleading or incorrect information in it. 117 By mandating a minimum amount of time 
and research on a product prior to the press release, this amendment could occur without 
too much extra cost and time to the FDA. This higher standard could also decrease the 
amount of allegations that the FDA included in their press releases and further dispel 
the opportunity for misinformation as the information trickled through social media. 
The FDA could ban allegations in press releases altogether. Alternatively, in cases of 
more significant risk or substantial harm, when the FDA needs to issue press releases, it 
should require expert opinions and caveat the release by indicating the case is currently 
an allegation, or that it lacks complete information. 118 
B. Due Notice 
Furthermore, the FDA should be required to offer some warning to manufacturers 
before suggesting publicly that the manufacturers have not complied with the FDCA. 
Due notice could mean that the FDA was required to give a reasonable amount of time 
for manufacturers and producers to be able to comment or even correct the issue that 
FDA found with the product, much like the standard voluntary recalls of the FDA. 119 
Such a notice and comment period would protect manufacturers from undue adverse 
publicity. 120 It might allow manufacturers to voluntarily recall potentially harmful 
products while maintaining public goodwill. Reasonable notice could even be limited to 
when the pending press release contains significant risk to either public health or (and 
possibly one leading to the other) significant economic risk to the manufacturer upon 
disclosure of the press release. 121 More than likely, if the FDA were more susceptible to 
tort liability, the agency might be more willing to provide reasonable notice. 
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C. Proper Terminations & Corrective Statements 
The FDA could also further the public health by becoming more willing and effective at 
amending or correcting press releases. The FDA should pay attention to new information 
and public response to its press releases, and respond when necessary. These back-end 
fixes to adverse publicity would provide some aid to manufacturers injured by misleading 
or misinformed press releases. 122 Corrective press releases would also considerably aid 
confused American consumers. Such follow-up press releases could report the final 
outcome of FDA investigations and summarize the underlying research and evidence. 123 
Given that the internet is a large cause of confusion and misinterpretation, the FDA 
could arguably try to oversee all internet commentary on FDA regulatory action. 124 
Because the use of social media has become so prolific, the FDA should incorporate 
social media into FAERS to monitor the public's reaction to press releases and to 
seek out adverse events to address. 125 Through the FDA's acceptance of an additional 
medium to communicate with the public, it could effectively decrease the amount of 
misinterpretation of FDA press releases, especially those leading to adverse publicity. 
Integrating social media with FAERS will allow the FDA to promptly offer a corrective 
follow up press release to cease confusion through its FAERS operator. 126 Twitter's one 
hundred and forty characters will be feared no more. 
D. Self-Restraint and Addressing Emergency Situations 
Considering that the FDA's ability to create adverse publicity for manufacturers greatly 
predated the Internet, the FDA should exercise more self-restraint overall. 127 The FDA 
is responsible for regulating a great number of products, many of which are potentially 
harmful or misleading to the public. However, the FDA does not need to issue public 
press releases about each one of those violations unless they are emergency situations. 
By exercising some self-restraint, the FDA would demonstrate that it is truly dedicated 
to public health and would also improve its relationships with manufacturers. 128 Self-
restraint by the FDA could also generate public support for a task force that will respond 
quickly to those products already on the market that pose imminent, serious threats to 
public health, but only when such a task force is completely necessary. With dedicated 
time and effort to study whatever available research exists and offer a recall or other 
advisement on the product as soon as trouble is found, such a task force would effectively 
guide the FDA to fulfilling its public service duty. 
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E. Emergency Taskforce 
An emergency task force will be extremely helpful at quickly responding to products 
like the LPM, which are already on the market and potentially harming the public. In 
such cases, the FDA cannot take five months or more to reach a conclusion. 129 Adverse 
publicity here is simply not enough, even if it may scare up conversation between 
patients and their healthcare providers. Because the FDA is the leading regulator of 
such products, it should also be the leader in the conversation as to how to approach 
the products. 130 As Dr. Reed pointed out in the LPM case, if the FDA fails to offer 
answers, it violates its duty to protect the public from potentially harmful and unsafe 
products. 131 An emergency taskforce can aid in the FD A's protection of the public by 
utilizing available information and conducting additional field research to determine 
whether an immediate response for a recall is required. 
V. APPLICATION OF THESE RECOMMENDATIONS TO THE 
LPMCRISIS 
In lieu of the second press release's resolution, the recommended amendments to FDA's 
use of publicity can be applied to the LPM crisis. The recommendations offer more 
effective and possibly less panic arousing public health communication methods to 
an agency committed to protecting consumers through the regulation of food, drugs, 
cosmetics, and medical devices. 
A.Research 
The FDA's first press release regarding the LPM did not offer any definitive conclusions, 
but merely suggested the LPM posed a "risk" that could worsen patients' survival. 132 
The harmful effects of LPM became more apparent after testimony surfaced in the 
FDA committee meetings with the Obstetrics and Gynecology Devices Panel and the 
subsequent FBI Investigation. 133 
The FDA admitted that there was little research on whether the LPM caused the later 
development ofuterine sarcomas. The FDA should have thought further, and recognized 
that eight studies and one abstract were not conclusive enough to announce that 1 in 
350 women relying on the LPM would later develop cancer. 134 Relying on a small 
number of studies and issuing a press release about a substantial public health issue 
may indicate that the lack of substantiation by the FDA caused the FDA to breach its 
duty to the public, or at least that there was a great deal of information left unturned. 135 
By increasing the minimum threshold requirement for research studies cited, the FDA 
could have had the support of more doctors and hospitals to support its position and 
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dissuade the use of the medical device. If the FDA utilized dissemination channels with 
direct access to patients: doctors, hospitals, and manufacturers, consumers would have 
been immediately informed and dissuaded against the use of the medical device. 
B. Due Notice 
Notice would be a more difficult concept to tackle here simply because the medical 
device industry under the regulation of the FDA is quite unlike the other consumer 
products regulated by the FDA in that the product is not available to the everyday 
consumer. However, if the FDA had given notice to both the manufacturers of the 
surgical medical device and the hospitals and doctors who used them, then there might 
have been a greater consolidation of the opinions regarding the medical device and 
furthermore, a better understanding of how to properly treat patients with or without it. 
There currently exists too much lag time between when information is available about 
when a device is unsafe and when the FDA issues a public determination that a device is 
unsafe. 136 Had the FDA notified device manufacturers, doctors, and hospitals earlier that 
it was committed to further researching ill health effects, there could have been a greater 
collaboration amongst everyone instead of the blowback the FDA received after issuing 
the press release. Although LPM was life-threatening, in a less dangerous context, both 
notification of industry personnel and consultation with experts provide stronger basis 
for the FDA to release adverse publicity. By collaborating its efforts, the FDA not only 
decreases the hostility the industry feels toward the agency, but it also increases the 
likelihood for voluntary participation in its device program effectiveness efforts. 
C. Emergency Taskforce 
The LPM is also a prime example of products already on the market potentially causing 
harm, which the FDA should investigate quickly. The FDA should not have taken nearly 
five months to report its advisory committee's findings in its second press release. The 
delay justifies distrust of the FDA as it currently operates and questions about whether 
the FDA is truly doing its best to protect the public welfare. If the FDA had an emergency 
taskforce when this crisis arose, it could have acted more quickly. 
CONCLUSION 
While the FDA is tasked with protecting the health of consumers by regulating products 
in the marketplace, its authority for use of publicity should be limited. 137 At the very 
least, the FDA must exercise care and minimize unnecessary harm to manufacturers and 
consumers. 138 This is particularly important as the FDA increasingly relies on adverse 
publicity to warn the public of potentially harmful products and threaten manufacturers 
to recall those products voluntarily. 139 
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Adverse publicity often creates the burden of stress for consumers, especially when a 
press release is later proven untrue or misrepresented. When consumers panic or fail to 
adequately understand FDA warnings, manufacturers suffer economically. Therefore, 
the FDA must gather adequate data and provide notice to manufacturers before issuing 
a press release containing adverse publicity. The FDA should also exhibit self-restraint 
on what to put into the media stream and be prepared to issue corrective statements 
and retractions in the case of false or misleading information. Congress can mandate 
these improvements by amending the FDCA or the APA, or the FDA can voluntarily 
implement these improvements. 
Combined, these changes would improve the FDA's ability to make public statements 
that effectively protect consumers from dangerous products without unduly punishing 
manufacturers with unreasoned adverse publicity. If the FDA conducts proper research 
and utilizes its resources, the next time a product raises immediate concern, the FDA 
will be able to expeditiously address the issue, keep consumers informed, and strengthen 
its relationship with regulated entities. 
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